Neoadjuvant Treatment Strategies for Resectable Proximal Gastric, Gastroesophageal Junction and Distal Esophageal Cancer

SIMPLE SUMMARY: The five-year survival for resectable proximal gastric, gastroesophageal junction (GEJ), and distal esophageal cancer ranges from 30 to 60% globally. Neoadjuvant and/or perioperative therapy has emerged as a treatment tool to improve patient selection for surgery, resectability, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmad, M. Usman, Javadi, Christopher, Poultsides, George A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996907/
https://www.ncbi.nlm.nih.gov/pubmed/35406527
http://dx.doi.org/10.3390/cancers14071755

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996907/
https://www.ncbi.nlm.nih.gov/pubmed/35406527
http://dx.doi.org/10.3390/cancers14071755

Ejemplares similares